Marksans Pharma Gestione
Criteri Gestione verificati 3/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Mark Saldanha
Amministratore delegato
₹63.8m
Compenso totale
| Percentuale dello stipendio del CEO | 75.28% |
| Mandato del CEO | 10.6yrs |
| Proprietà del CEO | 43.8% |
| Durata media del management | 11.7yrs |
| Durata media del Consiglio di amministrazione | 7.1yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Articolo di analisi • Feb 10
Marksans Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
It's been a pretty great week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, with its shares surging 13% to...Articolo di analisi • Jan 15
Marksans Pharma Limited's (NSE:MARKSANS) Shares May Have Run Too Fast Too Soon
It's not a stretch to say that Marksans Pharma Limited's ( NSE:MARKSANS ) price-to-earnings (or "P/E") ratio of 22.2x...Articolo di analisi • Dec 09
Here's Why Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt Responsibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • Nov 17
Analysts Have Made A Financial Statement On Marksans Pharma Limited's (NSE:MARKSANS) Second-Quarter Report
It's been a good week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, because the company has just released...
Aggiornamento della narrazione • Nov 11
MARKSANS: Upcoming Board Meeting And UK Regulatory Success Will Drive Momentum
Analysts have reduced their price target for Marksans Pharma from ₹231.67 to ₹216.67. They cite slight increases in the discount rate and a modest drop in the company's projected future price-to-earnings ratio as reasons for the adjustment.Articolo di analisi • Oct 15
Here's Why We Think Marksans Pharma (NSE:MARKSANS) Might Deserve Your Attention Today
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Aggiornamento della narrazione • Aug 15
Developed Markets Will Support Affordable Generic Expansion
Marksans Pharma's consensus price target has been revised downward, primarily due to sharply reduced revenue growth forecasts and a decline in net profit margin, lowering the fair value estimate from ₹301.00 to ₹231.67. What's in the News Board re-appointed Mr. Mark Saldanha as Managing Director, subject to shareholder approval at the upcoming AGM.Articolo di analisi • Aug 15
Marksans Pharma Limited (NSE:MARKSANS) Analysts Are Reducing Their Forecasts For This Year
NSEI:MARKSANS 1 Year Share Price vs Fair Value Explore Marksans Pharma's Fair Values from the Community and select...Articolo di analisi • Aug 07
Marksans Pharma Limited (NSE:MARKSANS) Doing What It Can To Lift Shares
NSEI:MARKSANS 1 Year Share Price vs Fair Value Explore Marksans Pharma's Fair Values from the Community and select...Articolo di analisi • Jun 28
Calculating The Intrinsic Value Of Marksans Pharma Limited (NSE:MARKSANS)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Marksans Pharma fair value estimate is ₹239 With ₹253 share...Articolo di analisi • May 27
We Think That There Are Some Issues For Marksans Pharma (NSE:MARKSANS) Beyond Its Promising Earnings
Marksans Pharma Limited's ( NSE:MARKSANS ) robust recent earnings didn't do much to move the stock. However the...Articolo di analisi • May 22
₹299: That's What Analysts Think Marksans Pharma Limited (NSE:MARKSANS) Is Worth After Its Latest Results
It's been a good week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, because the company has just released...Articolo di analisi • May 14
Should You Be Adding Marksans Pharma (NSE:MARKSANS) To Your Watchlist Today?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Articolo di analisi • Mar 23
Here's Why Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt Responsibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Articolo di analisi • Mar 05
Marksans Pharma Limited's (NSE:MARKSANS) P/E Is On The Mark
It's not a stretch to say that Marksans Pharma Limited's ( NSE:MARKSANS ) price-to-earnings (or "P/E") ratio of 24.6x...Articolo di analisi • Feb 15
Marksans Pharma Limited (NSE:MARKSANS) Just Reported Earnings, And Analysts Cut Their Target Price
It's been a mediocre week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, with the stock dropping 15% to...Articolo di analisi • Feb 01
Is Marksans Pharma Limited (NSE:MARKSANS) Expensive For A Reason? A Look At Its Intrinsic Value
Key Insights Marksans Pharma's estimated fair value is ₹190 based on 2 Stage Free Cash Flow to Equity Marksans Pharma's...
Nuova narrazione • Jan 28
Teva Pharma Facility And US Expansion To Strengthen Future Outlook
Strategic growth in the U.S. market and facility expansion bolster revenue growth, earnings, and profit margins through enhanced capacity and market share.Articolo di analisi • Nov 27
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Despite an already strong run, Marksans Pharma Limited ( NSE:MARKSANS ) shares have been powering on, with a gain of...Articolo di analisi • Oct 24
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Articolo di analisi • Sep 21
Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking
Marksans Pharma Limited ( NSE:MARKSANS ) shares have continued their recent momentum with a 45% gain in the last month...Articolo di analisi • Jul 28
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company
Marksans Pharma Limited ( NSE:MARKSANS ) shareholders would be excited to see that the share price has had a great...Articolo di analisi • Jun 07
Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
The market shrugged off Marksans Pharma Limited's ( NSE:MARKSANS ) solid earnings report. We did some digging and...Articolo di analisi • May 31
Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Articolo di analisi • Feb 16
Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)
When close to half the companies in India have price-to-earnings ratios (or "P/E's") above 32x, you may consider...Articolo di analisi • Jan 26
Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Articolo di analisi • Dec 02
We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • Jun 21
Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | ₹4b |
| Sep 30 2025 | n/a | n/a | ₹4b |
| Jun 30 2025 | n/a | n/a | ₹4b |
| Mar 31 2025 | ₹64m | ₹48m | ₹4b |
| Dec 31 2024 | n/a | n/a | ₹4b |
| Sep 30 2024 | n/a | n/a | ₹3b |
| Jun 30 2024 | n/a | n/a | ₹3b |
| Mar 31 2024 | ₹69m | ₹48m | ₹3b |
| Dec 31 2023 | n/a | n/a | ₹3b |
| Sep 30 2023 | n/a | n/a | ₹3b |
| Jun 30 2023 | n/a | n/a | ₹3b |
| Mar 31 2023 | ₹52m | ₹48m | ₹3b |
| Dec 31 2022 | n/a | n/a | ₹2b |
| Sep 30 2022 | n/a | n/a | ₹2b |
| Jun 30 2022 | n/a | n/a | ₹2b |
| Mar 31 2022 | ₹38m | ₹35m | ₹2b |
| Dec 31 2021 | n/a | n/a | ₹2b |
| Sep 30 2021 | n/a | n/a | ₹2b |
| Jun 30 2021 | n/a | n/a | ₹3b |
| Mar 31 2021 | ₹10m | ₹10m | ₹2b |
| Dec 31 2020 | n/a | n/a | ₹2b |
| Sep 30 2020 | n/a | n/a | ₹2b |
| Jun 30 2020 | n/a | n/a | ₹1b |
| Mar 31 2020 | ₹10m | ₹10m | ₹1b |
Compensazione vs Mercato: La retribuzione totale di Mark ($USD 665.86K ) è superiore alla media delle aziende di dimensioni simili nel mercato Indian ($USD 396.84K ).
Compensazione vs guadagni: La retribuzione di Mark è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Mark Saldanha (53 yo)
10.6yrs
Mandato
₹63,761,431
Compensazione
Mr. Mark B. Saldanha, M.Sc. (Maths) & (Stat.)., Dip. (Fin. Mgt.) serves as Promoter and Managing Director of Marksans Pharma Limited, which he joined in October 6, 2005 (alternate name, Glenmark Laboratori...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Non-Independent Executive Chairman & MD | no data | ₹63.76m | 43.8% ₹ 42.1b | |
| Group Chief Financial Officer | 23.7yrs | ₹17.99m | Nessun dato | |
| Company Secretary | 17.3yrs | ₹2.94m | Nessun dato | |
| Whole-Time Executive Non Independent Director | 11.7yrs | ₹7.07m | 0.073% ₹ 70.0m | |
| Whole-Time Executive Non Independent Director | 7.3yrs | ₹23.98m | Nessun dato | |
| Director Operations | no data | ₹5.80m | Nessun dato | |
| Managing Director of Australia Operations | no data | Nessun dato | Nessun dato | |
| Senior Vice President of QC | no data | ₹10.61m | Nessun dato | |
| Managing Director of UK Operations | no data | Nessun dato | Nessun dato | |
| Chief Operating Officer of US Operations | no data | ₹10.29m | Nessun dato | |
| Chief Executive Officer of EU Operations | 1.3yrs | Nessun dato | Nessun dato |
11.7yrs
Durata media
55.5yo
Età media
Gestione esperta: Il team dirigenziale di MARKSANS è esperto e expertise (durata media dell'incarico 11.7 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Non-Independent Executive Chairman & MD | 10.6yrs | ₹63.76m | 43.8% ₹ 42.1b | |
| Whole-Time Executive Non Independent Director | 11.7yrs | ₹7.07m | 0.073% ₹ 70.0m | |
| Whole-Time Executive Non Independent Director | 7.3yrs | ₹23.98m | Nessun dato | |
| Non-Executive & Non-Independent Director | 4.8yrs | Nessun dato | Nessun dato | |
| Non-Executive & Independent Director | 6.8yrs | ₹20.00k | Nessun dato | |
| Non-Executive Independent Director | 8.2yrs | ₹400.00k | Nessun dato | |
| Non-Executive & Independent Director | 3yrs | ₹400.00k | Nessun dato | |
| Independent Director | 1.3yrs | Nessun dato | Nessun dato |
7.1yrs
Durata media
54yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di MARKSANS sono considerati esperti (durata media dell'incarico 7.1 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/22 10:58 |
| Prezzo dell'azione a fine giornata | 2026/05/22 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/03/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Marksans Pharma Limited è coperta da 5 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Ranjit Kapadia | Centrum Broking Limited |
| Deepika Murarka | Choice Equity Broking Private Limited |
| Maitri Sheth | Choice Equity Broking Private Limited |